Regulus Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

Regulus Therapeutics

01/11/2021 11:23

* Regulus Therapeutics Inc  RGLS.OQ   RGLS.O  is expected
to show a fall in quarterly revenue when it reports results on
November 3 (estimated). 
* The San Diego, California-based company is expected to report 
a 99.9% decrease in revenue to $4.5 thousand from $5 million a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Regulus Therapeutics
Inc is for a loss of 8 cents per share. For the same quarter
last year, the company reported a loss of 4 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $1.5​, about 69.2% above​ its last closing
price of $0.46. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.08       -0.08      -0.08     Met     0
 Mar. 31 2021  -0.09       -0.09      -0.08     Beat    11.1
 Dec. 31 2020  -0.10       -0.14      -0.03     Beat    78.6​
 Sep. 30 2020  -0.22       -0.21      -0.04     Beat    80.7
 Jun.          -0.08​      -0.11      -0.23     Missed  -114​
 30​ 2020​                                              
 Mar. 31 2020  -0.16       -0.12      -0.25     Missed  -108.3
                                                        ​
 Dec. 31 2019  -0.23       -0.24      -0.23     Beat    4.2
 Sep. 30 2019  -0.26       -0.26      -0.26     Met     1
 This summary was machine generated November 1 at 11:22 GMT.  All
figures in US dollars unless otherwise stated